Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview of Pulmonary Circulation01:19

Overview of Pulmonary Circulation

4.7K
The pulmonary circulation is a vital system in our body that acts as a bridge between the respiratory and cardiovascular systems. It serves as a transport network for deoxygenated blood from the heart to the lungs and then returns oxygen-rich blood back to the heart.
The process begins with the right ventricle of the heart pumping deoxygenated blood into the pulmonary trunk. This large vessel extends about 5 centimeters before splitting into the left and right pulmonary arteries. These arteries...
4.7K
Anatomy of Respiratory System II: Lower Respiratory Tract01:31

Anatomy of Respiratory System II: Lower Respiratory Tract

5.2K
The lower respiratory tract is anatomically composed of several vital structures, including the larynx, trachea, bronchial tree, alveoli, lungs, and pleurae. Each component has a specific function, and all are intricately connected to ensure efficient respiration.
The Larynx
It is located between the pharynx and the trachea, acts as a passageway for air, and hosts several critical structures, such as the epiglottis, vocal cords, and glottis. The epiglottis acts as a gateway, guiding food to the...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy.

Cancers·2026
Same author

Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy.

Cancer·2026
Same author

Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer.

Clinical lung cancer·2025
Same author

Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024.

Cancer·2025

Related Experiment Video

Updated: Apr 3, 2026

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models
07:56

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models

Published on: November 11, 2020

4.9K

Lung-MAP--framework, overview, and design principles.

Renata Ferrarotto1, Mary W Redman2, David R Gandara3

  • 1Department of Thoracic and Head and Neck Medical Oncology, University of Texas, MD Anderson Cancer Center, USA.

Chinese Clinical Oncology
|September 27, 2015
PubMed
Summary
This summary is machine-generated.

Lung-MAP is a master protocol for metastatic lung squamous cell carcinoma (SCC) that matches patients to biomarker-targeted therapies. This adaptive trial design efficiently screens patients, improving outcomes for lung SCC.

Keywords:
Clinical triallung cancermaster protocolsquamous cell carcinoma (SCC)

More Related Videos

Three-Dimensional Phase Resolved Functional Lung Magnetic Resonance Imaging
10:44

Three-Dimensional Phase Resolved Functional Lung Magnetic Resonance Imaging

Published on: June 21, 2024

1.4K
Author Spotlight: Learning Systematic Bronchoscopy in a Simulation-Base Setting
04:47

Author Spotlight: Learning Systematic Bronchoscopy in a Simulation-Base Setting

Published on: June 23, 2023

3.9K

Related Experiment Videos

Last Updated: Apr 3, 2026

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models
07:56

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models

Published on: November 11, 2020

4.9K
Three-Dimensional Phase Resolved Functional Lung Magnetic Resonance Imaging
10:44

Three-Dimensional Phase Resolved Functional Lung Magnetic Resonance Imaging

Published on: June 21, 2024

1.4K
Author Spotlight: Learning Systematic Bronchoscopy in a Simulation-Base Setting
04:47

Author Spotlight: Learning Systematic Bronchoscopy in a Simulation-Base Setting

Published on: June 23, 2023

3.9K

Area of Science:

  • Oncology
  • Clinical Trials
  • Genomics

Background:

  • Metastatic lung squamous cell carcinoma (SCC) presents limited treatment options and poor prognoses.
  • Traditional clinical trials often fail to benefit most patients due to heterogeneity.
  • Biomarker-matched targeted therapies offer potential but face challenges with low-frequency alterations and high screen-failure rates.

Purpose of the Study:

  • To introduce the Lung-MAP (Lung Cancer Master Protocol) umbrella protocol for recurrent or metastatic lung SCC.
  • To describe Lung-MAP's innovative structure for efficient patient allocation to biomarker-matched trials.
  • To highlight the protocol's goal of improving treatment efficacy and patient outcomes.

Main Methods:

  • Lung-MAP utilizes a central genomic profiling platform for patient screening.
  • Patients are assigned to biomarker-matched phase II/III targeted therapy trials or a non-matched arm.
  • An adaptive design allows sub-studies to progress from phase II to phase III based on efficacy, incorporating prior patients.

Main Results:

  • The protocol ensures all screened eligible patients receive treatment under the protocol.
  • The adaptive structure facilitates efficient progression of promising treatments.
  • The design aims to expedite FDA approval for novel lung SCC therapies.

Conclusions:

  • Lung-MAP provides an efficient and adaptable framework for lung SCC research.
  • The protocol optimizes patient enrollment and treatment matching.
  • The ultimate goal is to significantly improve the quality and length of life for lung SCC patients.